Mimran, A. (Albert)

Search Results

Now showing 1 - 2 of 2
  • Thumbnail Image
    Pathophysiologic and therapeutic importance of tissue ACE: a consensus report
    (Springer Verlag, 2002) Hansson, L. (Lennart); Mimran, A. (Albert); Swedberg, K. (Karl); Johnston, C. (Colin); Hornig, B. (Burkhard); Drexler, H.G. (Hans G.); Lonn, E. (Eva); Mancini, J. (John); Weber, M. (Michael); Dahlöf, B. (Björn); Unger, T. (Thomas); Diez-Martinez, J. (Javier); Gilst, W. (Wiek) van; Celermajer, D. (David); Deanfield, J. (John); Ruzicka, M. (Marcel); Pepine, C. (Carl); Rabelink, T. (Ton); Remme, W. (Willem); Ferrari, R. (Roberto); Schunkert, H. (Heribert); Vaughan, D. (Douglas); Dzau, V.J. (Victor J.); Husain, A. (Ahsan); Lazar, H. (Harold); Cohen, J. (Jerome); Ruilope, L.M. (Luis M.); Bernstein, K. (Kenneth); Lüscher, T. (Thomas)
    Angiotensin-converting enzyme (ACE) activation and the de novo production of angiotensin II contribute to cardiovascular disease through direct pathological tissue effects, including vascular remodeling and inflammation, as well as indirect action on nitric oxide bioavailability and its consequences. The endothelium plays a pivotal role in both vascular function and structure; thus, the predominant localization of ACE to the endothelium has implications for the pathobiology of vascular disease, such as coronary artery disease. Numerous experimental studies and clinical trials support the emerging realization that tissue ACE is a vital therapeutic target, and that its inhibition may restore endothelial function or prevent endothelial dysfunction. These effects exceed those attributable to blood pressure reduction alone; hence, ACE inhibitors may exert an important part of their effects through direct tissue action. Pharmacologic studies show that while ACE inhibitors may differ according to their binding affinity for tissue ACE the clinical significance remains to be determined.
  • Thumbnail Image
    The relevance of tissue angiotensin-converting enzyme: manifestations in mechanistic and endpoint data
    (Elsevier, 2001) Hansson, L. (Lennart); Mimran, A. (Albert); Swedberg, K. (Karl); Johnston, C. (Colin); Hornig, B. (Burkhard); Lonn, E. (Eva); Mancini, J. (John); Weber, M. (Michael); Dahlöf, B. (Björn); Unger, T. (Thomas); Diez-Martinez, J. (Javier); Gilst, W. (Wiek) van; Celermajer, D. (David); Deanfield, J. (John); Ruzicka, M. (Marcel); Pepine, C. (Carl); Rabelink, T. (Ton); Remme, W. (Willem); Ferrari, R. (Roberto); Schunkert, H. (Heribert); Vaughan, D. (Douglas); Dzau, V.J. (Victor J.); Husain, A. (Ahsan); Lazar, H. (Harold); Drexler, H. (Helmut); Cohen, J. (Jerome); Ruilope, L.M. (Luis M.); Bernstein, K. (Kenneth); Lüscher, T. (Thomas)
    Angiotensin-converting enzyme (ACE) is primarily localized (>90%) in various tissues and organs, most notably on the endothelium but also within parenchyma and inflammatory cells. Tissue ACE is now recognized as a key factor in cardiovascular and renal diseases. Endothelial dysfunction, in response to a number of risk factors or injury such as hypertension, diabetes mellitus, hypercholesteremia, and cigarette smoking, disrupts the balance of vasodilation and vasoconstriction, vascular smooth muscle cell growth, the inflammatory and oxidative state of the vessel wall, and is associated with activation of tissue ACE. Pathologic activation of local ACE can have deleterious effects on the heart, vasculature, and the kidneys. The imbalance resulting from increased local formation of angiotensin II and increased bradykinin degradation favors cardiovascular disease. Indeed, ACE inhibitors effectively reduce high blood pressure and exert cardio- and renoprotective actions. Recent evidence suggests that a principal target of ACE inhibitor action is at the tissue sites. Pharmacokinetic properties of various ACE inhibitors indicate that there are differences in their binding characteristics for tissue ACE. Clinical studies comparing the effects of antihypertensives (especially ACE inhibitors) on endothelial function suggest differences. More comparative experimental and clinical studies should address the significance of these drug differences and their impact on clinical events.